RxDoctor Payments Data

Nicole Dreibelbis

Women's Health · Lancaster, PANPI 1639541675

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,778 of the $2,666 with a category attached, or 66.7%. 9 manufacturers reported payments, led by GSK at 46.4% of the total. Reporting peaked in 2024 at $1,260 and has fallen 67.9% since, to $405 in 2025. Among women's health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,666in general payments, 2019–2025

Across 32 payments — averaging $83.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$344
  • Eisai Inc.$256
  • AstraZeneca$241
  • Merck$208
  • Pfizer$118
  • plus $263 from 3 others

What the payments were for

  • Consulting fees$88833%
  • Food & beverage$1,77867%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$1,236
AbbVie4$344
Eisai Inc.6$256
AstraZeneca2$241
Merck5$208
Pfizer1$118
Genmab U.S., Inc.1$102
Seagen Inc.1$91
Immunogen, Inc.1$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,666 in reported general payments places this provider in the 90th percentile of 250 women's health providers in Pennsylvania.

See all women's health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,294
Medicare patients
127
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$8,971
Estradiol29$2,097
Megestrol Acetate16$1,576
Clobetasol Propionate11$693
Gabapentin15$321
Letrozole32$304
Nystatin16$246
Fluconazole26$181
Anastrozole12$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$8,97116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 women's health providers in Pennsylvania.

Other women's health in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →